Abstract OBJECTIVE: To study the antifungal treatment and intensive chemotherapy in children with acute leukemia and invasive aspergillosis. METHODS: The diagnosis and treatment of 4 cases of childhood acute leukemia complicated by invasive aspergillosis between July 2007 and July 2008 were studied retrospectively. RESULTS: Three children who underwent remission induction chemotherapy for ALL and one who underwent consolidation chemotherapy for AML developed invasive aspergillosis. One child with proven aspergillosis and 3 with possible aspergillosis all had halo sign on CT at diagnosis. Voriconazole or amphotericin B was given as primary therapy. Improvements of fungal lesions were shown by CT after two to four weeks of antifungal therapy. Complete radiologic remissions were achieved between 4 months and one year. The intensive chemotherapy schedule was continued in all of 4 cases. The median time from fungal infection to the continuation of chemotherapy was 35 days. None showed recurrence of fungal infection. CONCLUSIONS: The halo sign on CT may be a reliable indicator for the early diagnosis of invasive aspergillosis. The preemptive antifungal therapy on the basis of the identification of a halo sign and the reversal of immunosuppression may improve the outcome of invasive aspergillosis. Prolonged antifungal treatment during subsequent cycles of chemotherapy permits completion of scheduled intensive chemotherapy without fungal recurrence.［Chin J Contemp Pediatr, 2009, 11 (11):901-904］
LIU Ying,TANG Suo-Qin,WANG Jian-Wen et al. Treatment of acute leukemia complicated by invasive aspergillosis in children[J]. 中国当代儿科杂志, 2009, 11(12): 901-904.
LIU Ying,TANG Suo-Qin,WANG Jian-Wen et al. Treatment of acute leukemia complicated by invasive aspergillosis in children[J]. CJCP, 2009, 11(12): 901-904.
［1］Pagano L, Caira M, Picardi M, Candoni A, Melillo L, Fianchi L, et al. Invasive Aspergillosis in patients with acute leukemia: update on morbidity and mortality-SEIFEM-C Report［J］. Clin Infect Dis, 2007, 44(11):1524-1525.
［3］Caillot D, Couaillier JF, Bernard A, Casasnovas O, Denning DW, Mannone L, et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia［J］. J Clin Oncol, 2001, 19(1):253-259.
［4］Abramson S. The air crescent sign［J］. Radiology, 2001, 218(1):230-232.
［6］Greene RE, Schlamm HT, Oestmann JW, Stark P, Durand C, Lortholary O, et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign［J］. Clin Infect Dis, 2007, 44(3):373-379.
［7］Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, et al. Treatment of aspergillosis: clinical practice guidelines of the infectious diseases society of America［J］. Clin Infect Dis, 2008, 46(3):327-360.
［8］Nosari A, Oreste P, Cairoli R, Montillo M, Carrafiello G, Astolfi A, et al. Invasive aspergillosis in haematological malignancies: clinical finding and management for intensive chemotherapy completion［J］. Am J Hematol, 2001, 68(4):231-236.
［9］Mattei D, Mordini N, Lo Nigro C, Ghirardo D, Ferrua MT, Osenda M, et al. Voriconazole in the management of invasive aspergillosis in two patients with acute myeloid leukemia undergoing stem cell transplantation［J］. Bone Mattow Transplant, 2002, 30(12):967-970.
［10］Cordonnier C, Maury S, Pautas C, Bastié JN, Chehata S, Castaigne S, et al. Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients［J］. Bone Mattow Transplant, 2004, 33(9):943-948.
［11］Brodoefel H, Vogel M, Hebart H, Einsele H, Vonthein R, Claussen C, et al. Long-term CT follow-up in 40 non-HIV immunocompromised patients with invasive pulmonary aspergillosis: kinetics of CT morphology and correlation with clinical findings and outcome［J］. AJR Am J Roentgenol, 2006, 187(2):404-413.
